[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.168.209. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
This Week in JAMA
January 30, 2008

This Week in JAMA

JAMA. 2008;299(4):385. doi:10.1001/jama.299.4.385

Regulatory approval of currently available drug-eluting coronary stents was granted on the basis of results from relatively small clinical trials that enrolled highly selected patients. To assess outcomes in patients who are representative of “real world” clinical practice, investigators from the 5-center Danish Organization on Randomized Trials with Clinical Outcome (SORT OUT II) study randomly assigned 2098 patients undergoing primary coronary intervention to receive either sirolimus-eluting or paclitaxel-eluting stents to treat target lesions. Galløe and colleagues Article report that there were no significant differences in the composite clinical end point of either cardiac death, acute myocardial infarction (AMI), target lesion revascularization, or target vessel revascularization, or the secondary end points of total and cardiac mortality, AMI, or stent thrombosis among patients receiving either the sirolimus-eluting or paclitaxel-eluting stent. In an editorial, Mukherjee and Moliterno Article discuss the contributions and limitations of the SORT OUT II trial results for determining safe and effective revascularization practices.

×